[
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=46622f991f56c470f544a0e71116c00f61a3bf03155ba0189eb08d62a6841bae",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749054900,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 135048941,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=46622f991f56c470f544a0e71116c00f61a3bf03155ba0189eb08d62a6841bae"
    }
  },
  {
    "ts": null,
    "headline": "MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout",
    "summary": "MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.",
    "url": "https://finnhub.io/api/news?id=ac3e0bdbe8d76ea9e2aea5d249eea98ca128c909ef2c926d32e8320c50baa534",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749053160,
      "headline": "MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout",
      "id": 135035432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.",
      "url": "https://finnhub.io/api/news?id=ac3e0bdbe8d76ea9e2aea5d249eea98ca128c909ef2c926d32e8320c50baa534"
    }
  },
  {
    "ts": null,
    "headline": "Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.",
    "summary": "Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.",
    "url": "https://finnhub.io/api/news?id=88ebff88f22387e59485607455a562e18b78a458e1c5aa82cc84809645389d37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749052980,
      "headline": "Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.",
      "id": 135033565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.",
      "url": "https://finnhub.io/api/news?id=88ebff88f22387e59485607455a562e18b78a458e1c5aa82cc84809645389d37"
    }
  },
  {
    "ts": null,
    "headline": "PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo",
    "summary": "Wells Fargo analyst Mohit Bansal notes that PTAB has instituted Merck’s (MRK) patent grant review against Halozyme Therapeutics (HALO) MDASE patents. This patent is one of the patents Merck is fighting against Halozyme. The firm believes this likely reduces the probability of Halozyme prevailing in this case and weakens the bull argument. Wells has an Equal Weight on Halozyme with a price target of $65 on the shares. Published first on TheFly – the ultimate source for real-time, market-moving br",
    "url": "https://finnhub.io/api/news?id=acb095248918d77781974c8fc8c13b9a8fe740b02e449d5b21939d3e33618a84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749041714,
      "headline": "PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo",
      "id": 135011314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Wells Fargo analyst Mohit Bansal notes that PTAB has instituted Merck’s (MRK) patent grant review against Halozyme Therapeutics (HALO) MDASE patents. This patent is one of the patents Merck is fighting against Halozyme. The firm believes this likely reduces the probability of Halozyme prevailing in this case and weakens the bull argument. Wells has an Equal Weight on Halozyme with a price target of $65 on the shares. Published first on TheFly – the ultimate source for real-time, market-moving br",
      "url": "https://finnhub.io/api/news?id=acb095248918d77781974c8fc8c13b9a8fe740b02e449d5b21939d3e33618a84"
    }
  },
  {
    "ts": null,
    "headline": "Merck granted review of Halozyme patent claims by PTAB",
    "summary": "The USPTO’s Patent Trial and Appeal Board instituted Merck’s (MRK) patent grant review against Halozyme’s (HALO) MDASE patents after Merck filed a Petition requesting post-grant review of claims 1-21 of U.S. Patent No. 11,952,600, according to a post to the site of the USPTO. In consideration of “the Petition, Preliminary Response, Reply, Sur-Reply, and the evidence of record, we determine that the information presented shows that it is more likely than not that Petitioner would prevail in estab",
    "url": "https://finnhub.io/api/news?id=1018a326a692fd0639fbe69bee689fa697fbeceec1c0de1ff8a768e4d599cc64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749041415,
      "headline": "Merck granted review of Halozyme patent claims by PTAB",
      "id": 135011315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The USPTO’s Patent Trial and Appeal Board instituted Merck’s (MRK) patent grant review against Halozyme’s (HALO) MDASE patents after Merck filed a Petition requesting post-grant review of claims 1-21 of U.S. Patent No. 11,952,600, according to a post to the site of the USPTO. In consideration of “the Petition, Preliminary Response, Reply, Sur-Reply, and the evidence of record, we determine that the information presented shows that it is more likely than not that Petitioner would prevail in estab",
      "url": "https://finnhub.io/api/news?id=1018a326a692fd0639fbe69bee689fa697fbeceec1c0de1ff8a768e4d599cc64"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference",
    "summary": "RAHWAY, N.J., June 04, 2025--Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference",
    "url": "https://finnhub.io/api/news?id=5eedbf0f55abfc255e0b86958d74ccdfa06e147ad6d1688e9358f078b53ef85b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749033900,
      "headline": "Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference",
      "id": 135011316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., June 04, 2025--Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference",
      "url": "https://finnhub.io/api/news?id=5eedbf0f55abfc255e0b86958d74ccdfa06e147ad6d1688e9358f078b53ef85b"
    }
  },
  {
    "ts": null,
    "headline": "Health Rounds: Older breast cancer patients using estrogen cream live longer, study finds",
    "summary": "In older women diagnosed with breastcancer, use of estrogen creams to treat menopause symptoms wasnot only safe but was also linked with longer survival in alarge U.S. study. Use of...",
    "url": "https://finnhub.io/api/news?id=b551f972a8b14a8f5e6d1bb7a2a0866ca34f2325b061e2c92ed9380b630b8ba3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749020434,
      "headline": "Health Rounds: Older breast cancer patients using estrogen cream live longer, study finds",
      "id": 135007710,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "In older women diagnosed with breastcancer, use of estrogen creams to treat menopause symptoms wasnot only safe but was also linked with longer survival in alarge U.S. study. Use of...",
      "url": "https://finnhub.io/api/news?id=b551f972a8b14a8f5e6d1bb7a2a0866ca34f2325b061e2c92ed9380b630b8ba3"
    }
  },
  {
    "ts": null,
    "headline": "1 Value Stock to Target This Week and 2 to Question",
    "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.",
    "url": "https://finnhub.io/api/news?id=45de38f83c9baeeae9505bd065a2912727d3c53bdbad7d6608e6825de4445914",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749011672,
      "headline": "1 Value Stock to Target This Week and 2 to Question",
      "id": 135010115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.",
      "url": "https://finnhub.io/api/news?id=45de38f83c9baeeae9505bd065a2912727d3c53bdbad7d6608e6825de4445914"
    }
  }
]